NexImmune (NASDAQ:NEXI) Posts Quarterly Earnings Results

NexImmune (NASDAQ:NEXI) announced its quarterly earnings data on Friday. The company reported ($9.40) earnings per share (EPS) for the quarter, reports.

NexImmune Price Performance

NexImmune stock opened at $2.48 on Monday. The firm’s 50 day simple moving average is $4.29 and its 200-day simple moving average is $6.19. The company has a market cap of $2.59 million, a P/E ratio of -0.06 and a beta of 2.16. NexImmune has a fifty-two week low of $2.30 and a fifty-two week high of $20.35.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in NEXI. Slate Path Capital LP purchased a new position in NexImmune during the first quarter valued at approximately $352,000. First Manhattan CO. LLC. grew its position in NexImmune by 496.4% during the first quarter. First Manhattan CO. LLC. now owns 149,110 shares of the company’s stock valued at $57,000 after purchasing an additional 124,110 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in NexImmune during the first quarter valued at approximately $31,000. Citigroup Inc. purchased a new position in NexImmune during the first quarter valued at approximately $304,000. Finally, Raymond James & Associates grew its position in NexImmune by 947.0% during the first quarter. Raymond James & Associates now owns 320,622 shares of the company’s stock valued at $122,000 after purchasing an additional 290,000 shares in the last quarter. 26.26% of the stock is owned by hedge funds and other institutional investors.

NexImmune Company Profile

NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.